KALV - カ―ビラン・セラピュ―ティクス (KalVista Pharmaceuticals Inc.)

KALVのニュース

   Kalvista Pharmaceuticals Inc (NASDAQ:KALV) Insider Sells $138,905.58 in Stock  2020/10/25 09:38:41 Zolmax News
Kalvista Pharmaceuticals Inc (NASDAQ:KALV) insider Christopher Yea sold 7,942 shares of the stock in a transaction on Tuesday, October 20th. The shares were sold at an average price of $17.49, for a total transaction of $138,905.58. Following the completion of the sale, the insider now directly owns 76,315 shares of the company’s stock, valued at […]
   Thomas Andrew Crockett Sells 15,994 Shares of Kalvista Pharmaceuticals Inc (NASDAQ:KALV) Stock  2020/10/22 19:44:47 US Banking News
Kalvista Pharmaceuticals Inc (NASDAQ:KALV) CEO Thomas Andrew Crockett sold 15,994 shares of the business’s stock in a transaction dated Tuesday, October 20th. The shares were sold at an average price of $17.49, for a total transaction of $279,735.06. Following the transaction, the chief executive officer now owns 222,741 shares in the company, valued at approximately […]
   Thomas Andrew Crockett Sells 1,261 Shares of Kalvista Pharmaceuticals Inc (NASDAQ:KALV) Stock  2020/10/22 09:26:42 Zolmax News
Kalvista Pharmaceuticals Inc (NASDAQ:KALV) CEO Thomas Andrew Crockett sold 1,261 shares of the firm’s stock in a transaction that occurred on Friday, October 16th. The stock was sold at an average price of $17.01, for a total transaction of $21,449.61. Following the completion of the sale, the chief executive officer now owns 236,959 shares in […]
   Insider Selling: Kalvista Pharmaceuticals Inc (NASDAQ:KALV) CEO Sells 1,261 Shares of Stock  2020/10/20 18:38:43 Transcript Daily
Kalvista Pharmaceuticals Inc (NASDAQ:KALV) CEO Thomas Andrew Crockett sold 1,261 shares of the business’s stock in a transaction on Friday, October 16th. The shares were sold at an average price of $17.01, for a total transaction of $21,449.61. Following the completion of the sale, the chief executive officer now directly owns 236,959 shares in the […]
   KalVista Pharmaceuticals Provides Update on Oral Hereditary Angioedema Franchise  2020/10/15 11:00:00 Business Wire
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an update on its franchise of oral therapies for treatment of hereditary angioedema (HAE). “We have completed enrollment of our Phase 2 trial for our oral on-demand HAE treatment, KVD900, and remain on track to deliver data before the end of
   KalVista Pharmaceuticals Reports First Fiscal Quarter Results  2020/09/14 11:00:00 Business Wire
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the first fiscal quarter ended July 31, 2020. “We are pleased that our KVD900 Phase 2 trial has met its enrollment target and data is expected before the end of this year. We believe K
   KalVista Pharmaceuticals to Present at Cantor Global Healthcare Conference  2020/09/11 11:00:00 Business Wire
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at the Cantor Fitzgerald Virtual Global Healthcare Conference on Thursday, September 17, 2020 at 8:40 am ET. A live webcast of the presentation will be available on the Company’s website at www.kalvista.com. An audio ar
   KalVista Pharmaceuticals to Present at BTIG Virtual Biotechnology Conference  2020/08/03 11:30:00 Business Wire
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at the BTIG Virtual Biotechnology Conference on Monday, August 10, 2020, at 1:00 p.m. ET. A live webcast of the presentation will be available on the Company’s website at www.kalvista.com. An audio archive will be avail
   KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results | | IT Business Net  2020/07/01 12:02:15 IT Business Net
– KVD900 Phase 2 Clinical Trial for Oral Treatment of Hereditary Angioedema (HAE) Data Expected in 2H 2020 – – Oral HAE Prophylactic Candidate KVD824 Phase 2
   KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results  2020/07/01 11:00:00 Business Wire
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors today provided an operational update and released financial results for the fiscal year ended April 30, 2020. “We have two oral candidates in clinical trials that have the potential to provide HAE patients with a complete set of options to treat their disea
   KalVista Pharmaceuticals Reports First Fiscal Quarter Results  2020/09/14 11:00:00 Business Wire
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the first fiscal quarter ended July 31, 2020. “We are pleased that our KVD900 Phase 2 trial has met its enrollment target and data is expected before the end of this year. We believe K
   KalVista Pharmaceuticals to Present at Cantor Global Healthcare Conference  2020/09/11 11:00:00 Business Wire
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at the Cantor Fitzgerald Virtual Global Healthcare Conference on Thursday, September 17, 2020 at 8:40 am ET. A live webcast of the presentation will be available on the Company’s website at www.kalvista.com. An audio ar
   KalVista Pharmaceuticals to Present at BTIG Virtual Biotechnology Conference  2020/08/03 11:30:00 Business Wire
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at the BTIG Virtual Biotechnology Conference on Monday, August 10, 2020, at 1:00 p.m. ET. A live webcast of the presentation will be available on the Company’s website at www.kalvista.com. An audio archive will be avail
   KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results | | IT Business Net  2020/07/01 12:02:15 IT Business Net
– KVD900 Phase 2 Clinical Trial for Oral Treatment of Hereditary Angioedema (HAE) Data Expected in 2H 2020 – – Oral HAE Prophylactic Candidate KVD824 Phase 2
   KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results  2020/07/01 11:00:00 Business Wire
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors today provided an operational update and released financial results for the fiscal year ended April 30, 2020. “We have two oral candidates in clinical trials that have the potential to provide HAE patients with a complete set of options to treat their disea

calendar